- Question from rebecca: What was the most encouraging news you heard at the San Antonio conference this year?
- Answers - Kathy D. Miller, M.D. I think it was the Phase III trial comparing denosumab to Zometa in women with metastatic disease involving the bones. This is an important and common problem for women with metastatic disease. Denosumab was more effective and had fewer side effects, and I think will be a big advance for our patients.
On Tuesday, December 15, 2009, our Ask-the-Expert Online Conference was called Updates from the 2009 San Antonio Breast Cancer Symposium. Kathy Miller, M.D. and Kristin Brill, M.D., F.A.C.S. answered your questions about the latest updates on breast cancer risk, screening techniques, treatment options, and more.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.